Thursday, October 22, 2026

Broadcom AI Revenue Surges 106% While Non-AI Business Flatlines, Stock Declines

Broadcom reported AI revenue growth of 106% year-over-year, with AI networking accounting for one-third of AI sales and growing 60%. Non-AI revenues remained flat at $4.1 billion, highlighting a bifurcation that sent shares lower despite strong AI performance.

LM Salvado
LM Salvado

April 10, 2026

Broadcom AI Revenue Surges 106% While Non-AI Business Flatlines, Stock Declines
Image generated by AI for illustrative purposes. Not actual footage or photography from the reported events.
Loading stream...

Broadcom's latest earnings revealed a stark revenue split: AI-related segments jumped 106% year-over-year while non-AI revenues stagnated at $4.1 billion.1 The divergence signals a market shift where investors are differentiating between AI and legacy business performance rather than rewarding total growth.

AI networking revenues grew 60% year-over-year and represented one-third of total AI revenues.1 The networking segment's growth demonstrates expanding infrastructure demand beyond core AI processing chips. Despite these gains, Broadcom stock declined following the earnings release.1

The stock decline despite triple-digit AI growth suggests investors are applying new valuation frameworks. Companies with flat non-AI segments face pressure even when AI divisions perform strongly. This creates strategic questions about resource allocation and whether legacy businesses drag on overall valuations.

The pattern extends beyond Broadcom. AI-exposed tech companies now face scrutiny on segment-level performance rather than consolidated results. Investors want visibility into which revenue streams drive growth and how much of the business remains tied to slower-moving markets.

For companies reporting mixed results, the market appears to discount strong AI performance when paired with stagnant core operations. This valuation pressure could accelerate strategic decisions: divesting non-AI units, increasing AI investment, or restructuring to highlight AI exposure.

Broadcom's experience tests a hypothesis about revenue bifurcation across AI-focused companies. If AI segments consistently grow above 100% while traditional segments flatline, companies face questions about long-term composition and whether diversified portfolios still command premium multiples.

The shift affects how investors analyze quarterly reports. AI revenue growth rates now matter more than total revenue growth. Companies that break out AI performance clearly may receive better valuations than those reporting only consolidated numbers, even with similar overall results.

In this story · Knowledge Files

About this analysis

This is a Via News analysis. It synthesizes signals, events and patterns across our coverage rather than deriving from a single source document, so it carries no external source pointer. Via News is a conduit: where a claim traces to a specific document, we link it. How we source

LM Salvado
LM Salvado

LM Salvado is an AI possibilist — he takes the risks of AI seriously, and still sees the route through them. Founder of Via News Agency, an AI-native newsroom built on full source-traceability, he tracks how AI is reshaping markets, capital, and labor — the quiet shifts that happen before the headlines catch up.

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Q4 2026 Biopharma Catalyst Crunch: Late-Stage Readouts and Regulatory Milestones Converge on the Ivonescimab PDUFA Date
October 2026 is dense with clinical and regulatory news. Phase 3 trials hit primary endpoints (ALOFT-IPF, RESTORE-3), long-term data came out (MIUDELLA at 6 years, QUILT-3.032), and the FDA accepted Roche's vamikibart BLA. Scholar Rock resubmitted its apitegromab MAA to the EMA. The next catalysts are ESMO 2026 (Oct 23) and the Nov 14 FDA PDUFA date for ivonescimab, followed by Maritime-1 primary completion in January 2027. The speculative QAIAx items (QIII pilot, microcities patent) are a weak, tangential thread with little financial substance.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,986
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,986 facts checked against source5,426 source documents archived
Query this data → isubstrate.com